Company: TVRD
Filing Date: 2025-01-27
Form Type: S-4/A
Source: 0001104659-25-006050
Chunk: 17

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-01-27
Form: S-4/A
Chunk 17
---
 “Management Following the Merger” beginning on page 18 of this proxy statement/prospectus. |

Q: Who will be the executive officers of Cara following the Merger?

| A: | Immediately following the Merger, the executive management team of the combined company is expected to comprise the following individuals with such additional officers as may be added by the combined company: |

| ​                           | ​ | Position with the                                     | ​ | ​                                                     |
| Name                        |   | Combined Company                                      |   | Current Position at Tvardi                            |
| Imran Alibhai, Ph.D.        | ​ | Chief Executive Officer and Director                  | ​ | Chief Executive Officer and Director                  |
| Dan Conn, J.D., M.B.A.      | ​ | Chief Financial Officer                               | ​ | Chief Financial Officer                               |
| John Kauh, M.D.             | ​ | Chief Medical Officer                                 | ​ | Chief Medical Officer                                 |
| Jeffrey Larson, Ph.D., DABT | ​ | Senior Vice President, Research & Development         | ​ | Senior Vice President, Research & Development         |
| Yixin “Joseph” Chen, Ph.D.  | ​ | Vice President, Chemistry, Manufacturing and Controls | ​ | Vice President, Chemistry, Manufacturing and Controls |

Q: As a stockholder of Cara, how does the Cara Board recommend that I vote?

| A: | After careful consideration, the Cara Board recommends that the holders of Cara common stock vote: |

| ● | “FOR” Proposal 1 — the Stock Issuance Proposal; |

| ● | “FOR” Proposal 2 — the Equity Plan Proposal; |

| ● | “FOR” Proposal 3 — the ESPP Proposal; |

| ● | “FOR” Proposal 4 — the Reverse Stock Split Proposal; |

| ● | “FOR” Proposal 5 — the Authorized Share Proposal; |

| ● | “FOR” Proposal 6 — the Compensation Proposal; and |

| ● | “FOR” Proposal 7 — the Adjournment Proposal. |

For more information on each proposal and the Cara Board’s recommendations, please see the section titled “ Matters Being Submitted to a Vote of Cara’s Stockholders” beginning on page 199 of this proxy statement/prospectus. Q: How many votes are needed to approve each Cara Proposal?

| A: | Approval of each of the Stock Issuance Proposal, the Equity Plan Proposal, the ESPP Proposal, the Reverse Stock Split Proposal and the Authorized